Drugs / [18F]AlF-PSMA-N5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06756334 | Dec 2024 → Jun 2025 overdue | prostate cancer | Anhui Provincial Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]AlF-PSMA-N5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756334 ↗ |
| Modality | Diagnostic / imaging agent | “novel PET imaging agent \[18F\]AlF-PSMA-N5” NCT06756334 ↗ |
| Route | Intravenous | “Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.” NCT06756334 ↗ |